Treatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA

Plasma cell-free DNA levels and integrity in patients with chest radiological findings: NSCLC versus benign lung nodules

(2016) Adam Szpechcinski et al.   CANCER LETTERS

Detection of Hot-Spot Mutations in Circulating Cell-Free DNA From Patients With Intraductal Papillary Mucinous Neoplasms of the Pancreas

(2016) Andreas W. Berger et al.   GASTROENTEROLOGY

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations

(2016) Sabrina Arena et al.   Science Translational Medicine

Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer

(2016) Jeanne Tie et al.   Science Translational Medicine

Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer

(2015) J. Tie et al.   ANNALS OF ONCOLOGY

Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease

(2015) A Szpechcinski et al.   BRITISH JOURNAL OF CANCER

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial

(2015) Josep Tabernero et al.   LANCET ONCOLOGY

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

(2015) Giulia Siravegna et al.   NATURE MEDICINE

Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer

(2015) M. Russo et al.   Cancer Discovery

Circulating Free DNA as Biomarker and Source for Mutation Detection in Metastatic Colorectal Cancer

(2015) Karen Lise Garm Spindler et al.   PLoS One

Liquid Biopsies: Genotyping Circulating Tumor DNA

(2014) Luis A. Diaz et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA

(2014) Alain R Thierry et al.   NATURE MEDICINE

Detection of Methylated Septin 9 in Tissue and Plasma of Colorectal Patients with Neoplasia and the Relationship to the Amount of Circulating Cell-Free DNA

(2014) Kinga Tóth et al.   PLoS One

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

(2014) C. Bettegowda et al.   Science Translational Medicine

Phase II trial of temsirolimus alone and in combination with irinotecan forKRASmutant metastatic colorectal cancer: Outcome and results ofKRASmutational analysis in plasma

(2013) Karen-Lise G. Spindler et al.   ACTA ONCOLOGICA

BRAFmutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel

(2013) D. Gonzalez et al.   BRITISH JOURNAL OF DERMATOLOGY

Detection of Circulating Pancreas Epithelial Cells in Patients With Pancreatic Cystic Lesions

(2013) Andrew D. Rhim et al.   GASTROENTEROLOGY

ALKin Lung Cancer: Past, Present, and Future

(2013) Alice T. Shaw et al.   JOURNAL OF CLINICAL ONCOLOGY

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

(2013) Muhammed Murtaza et al.   NATURE

Implementing personalized cancer genomics in clinical trials

(2013) Richard Simon et al.   NATURE REVIEWS DRUG DISCOVERY

RECIST: No Longer the Sharpest Tool in the Oncology Clinical Trials Toolbox--Point

(2012) M. R. Sharma et al.   CANCER RESEARCH

EMT and Dissemination Precede Pancreatic Tumor Formation

(2012) Andrew D. Rhim et al.   CELL

Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan

(2012) K.-L. G. Spindler et al.   CLINICAL CANCER RESEARCH

Comprehensive molecular characterization of human colon and rectal cancer

(2012)   NATURE

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA

(2012) T. Forshew et al.   Science Translational Medicine

Cell-free DNA in the blood as a solid tumor biomarker—A critical appraisal of the literature

(2010) Klaus Jung et al.   CLINICA CHIMICA ACTA

Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts

(2010) Alain R. Thierry et al.   NUCLEIC ACIDS RESEARCH

American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy

(2009) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer

(2008) M. Frattini et al.   CANCER LETTERS

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107

(2008) Axel Grothey et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)

(2008) Axel Grothey et al.   JOURNAL OF CLINICAL ONCOLOGY

Circulating mutant DNA to assess tumor dynamics

(2008) Frank Diehl et al.   NATURE MEDICINE